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ABSTRACT 
Nano-sized objects can be transformed in many ways to alter their characteristics. Drug molecules sized in nanometer provide some unique 
features which can lead to improved drug localization, prolonged circulation, 5 and enhanced drug efficacy of the drug. Nanotechnology 
improves the performance come through a variety of dosage forms. Various pharmaceutical nanotechnology based systems which can be 
termed as Nanopharmaceuticals like liposomes, carbon Nanotubes, quantum dots, dendrimers, and polymeric nanoparticles. This review 
summarizes the most important applications of nanotechnology.The purpose of that review paper is to look into the present aspects of 
“Nanotechnology”. This paper gives a brief description of what Nanotechnology is? And its application in various fields like computing, 
medicine, food technology, Robotics, Solar cells etc. Nanotechnology also deals with the future perspectives of Nanotechnology, risks in 
advanced nanotechnology. 
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INTRODUCTION 
Nanotechnology and Nanomedicines 
Nanotechnology and Nanomedicines, the high risk, high pay 
off global phenomenon is in full swing. Advances of 
nanotechnology are being driven by collaborative research, 
patenting, commercialization, business development and 
technology transfer within diverse areas such as chemical 
engineering, biotechnology, the medical sciences, physical 
sciences and information technology [1-3]. 
The confusion and ambiguity surrounding the definition of 
nanotechnology continues to be one of the most significant 
problems shared by regulators, policymakers, researchers 
and legal professionals alike. Different definitions of 
nanotechnology have sprung up over the years. 
Nanotechnology has been described as the manipulation, 
precision placement, measurement, modeling or 
manufacture of matter in the sub‐100 nm range [4], or in the 
1 to 200 nm range.  
Size reduction is important applications in pharmacy. Size 
reduction improving solubility and bioavailability, reducing 
toxicity, enhancing release. It providing better formulation 
opportunities for drugs. In some of the cases, size reduction 
is limited to micron size range, for example, various 
pharmaceutical dosage forms like powder, emulsion, 
suspension etc. Drugs in the nanometer size range improve 
performance in a variety of dosage forms. Major advantages 
of nanosizing include: 
(i) increased surface area, 
(ii) enhanced solubility, 
(iii) increased rate of dissolution, 
(iv) increased oral bioavailability, 
(v) more rapid onset of therapeutic action, 
(vi) less amount of dose required, 
(vii) decreased fed/fasted variability, and 
(viii) decreased patient-to-patient variability 
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Table 1 :-Definitions of general  nanotechnology:relatedterms 
      Term                           Defination 
1 Nanomaterial Material with one or more external dimensions, or an internal structure, on the nanoscale, 
which could exhibit novel characteristics compared to the same material without nanoscale 
features NOTE Novel characteristics might include increased strength, chemical reactivity or 
conductivity. 
2 Nanoparticle Particle with one or more dimensions at the nanoscale NOTE 1 Also referred to as 
nanoparticulate, although this term is more often used adjectivally. NOTE 2 Novel 
properties that differentiate nanoparticles from the bulk material are typically developed at 
a critical length scale of under 100 nm. 
3 Nanoscale Having one or more dimensions of the order of 100 nm or less. NOTE Also referred to as 
nanosize. 
4 Nanoscience Study of phenomena and manipulation of materials at atomic, molecular and 
macromolecular scales, where properties differ significantly from those at a larger scale 
5 Nanostructured Having a structure at the nanoscale NOTE Agglomerates and aggregates of nanoparticles are 
examples of nanostructured particles. 
6 Nanotechnology Design, characterization, production and application of structures, devices and systems by 
controlling shape and size at the nanoscale  
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Table 2:- problematic soial trads and ways nanotechnology could contribute to solution, according to Roco and 
Bainbridge 
Social problems Nanotechnology contribution to solution 
Health care and working capacity of 
aging polution  
Convergence of nanotechnology with bitechnology, information technology 
and neurotechnology would adress chronic illness,losing senserial property, 
capacity, and maintainng work capacity. 
Collapse of birth rate in most advanced 
nations, below level required for 
population stability. 
Convergance of nanotechnology with biotechnology to overcome infertility. 
Poverty and inequality, most urgently in 
under developed nations  
Economic progress,fueled by technological development requiring systemic 
control of nanoscale processes and materils. 
Loss of jobs in advanced nations, as 
work goes to nations with lower wages, 
weaker workers benefits, andworse 
workplace safety. 
Progress in nanosence will allow industrial nations to maintain quality of life, 
generating new domestic industries with high quality jobs, even as poor 
nations benefits from globalization. 
Threanted exhusion of natural 
resources. 
Non-enalbed technologiesfor improved efficancy in use of non-renewable 
resources, inclouding energy production, water filteration, and invention of 
many high quality nano-fabricated substitute materials. 
Environmental degradation, including 
global warming. 
Reduced pollution from more efficient use of materials: specific new pollution 
remedition nanotechnoloies: improved environmental monitoring by means 
nano-enabled sensor nets. 
World political instability theatens the 
gains achieved by newly denocratic 
nations. 
Stability will require technology that can offer abundance to a majority of 
people in all socities with existing natural resourecs. 
Security issues within industrial nations. Numerous specific nanotechnalogy-based solutions; such as;sensors to detect 
bioterrorism substances: inexpensive “smart labels” to deter theft of valuable 
goods; armor and vehical components from nano-structed materials. 
Cultural chaos in post-industrial, post-
modern,pluralist society. 
Nantechnology will permit rapid process  in technologies of compulation, 
communication and creativity to sustain a culture of connectively, equal 
access to information and a myriad subcultures simultaneously. 
Medical;currently incurable illness 
including cancer and AIDS 
Molucular and nanobiosystems solutions for detection and treatment and the 
subcellular level. 
Medical: diminishing returns from 
research; rising costs of health care 
Fresh approaches to disease diagnosis and treatment from 
nanotechnology;prevension of disease from better nutrition and from quick 
detection and treatment of condition predisposing to disease. 
 
CLASSIFICATION OF NANOPHARMACEUTICALS:- 
CANRBON NANOTUBES:- 
Carbon  Nanotubes (CNTs) are hollow, well ordered, carbon 
nanomaterial.CNTs have  variety of properties. These have 
high aspect ratio and surface area, and ultra-light 
weight.CNTs are classified as single-walled (SW) or multi-
walled (MW) carbon Nanotubes. In that MWCNTs are made 
from a number of cylindrical carbon layers and have 
diameter 2-100 nm, and SWCMTs consists only one 
cylindrical layer and have diameter ranges from 0.4–2 nm. 
[5] CNTs provide a greater targeting ability to the 
formulations. following examples  are presented inTable-3
 
Table3:- Drugs those can be delivered via Carbon Nanotubes 
            Drug  Type of disease Type of CNTs 
Daunorubicin Leukemia SWCNTs 
Doxorubicin  Lymphoma SWCNTs 
 Breast cancer MWCNTs 
Methotrexate Breast cancer MWCNTs 
Paclitaxel Breast cancer SWCNTs 
Gemcitabine Ovarian cancer SWCNTs 
Amphotericin B Leishmania  donovani Not specified 
Carboplastin Bladder cancer Not specified 
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QUANTUM DOTS:- 
Quantum dots (QDs) have semiconductor core andcoated by 
a shell which improved optical properties. These have  a cap 
which provides higher solubility in aqueous buffers. 
Functionalized QDs, conjugating them with targeting ligands, 
and  used to target specific tissues. Various colloidal 
core/shell usually synthesized by are CdSe/ZnS, CdTe/CdSe, 
InP/ZnS and CdSe/CdS/ZnS [6].QDs have a potential for 
improved treatment of cancer.Before that, while preparing 
QD-drug formulations, some guidelines must be followed  
(a)Surface of nanoparticles must be functionalized 
(b)Nanoparticle size is to be minimized  
(c)To avoid detrimental effects of the drug,drug molecules 
should be kept within the nanoparticle  
(d)To avoid collapse, a biocompatible polymer must be 
attached to QD surface.  
Some of drugs successfully delivered by QDs are listed in 
Table-4
 
Table4:- Drugs those can be delivered via Quantum Dose 
 
DENDRIMERS:- 
Dendrimers are highly branched Nano-scale structure with 
several surface-active groups.These have smaller size (<100 
nm),and due to that narrower molecular weight distribution, 
greater functionality, higher quantity of surface groups and 
relatively easier incorporation of targeting ligands.They are 
very good candidates for drug delivery. The main 
characteristics which make it special are three different 
topological sites A 
(a) Polyfunctional core 
 (b) Interior layers and  
(c) multivalent surface[7] 
 
Table5:- drugs those delivered via Dendrimers 
Drugs / therapeutics Types of Dendrimers 
/Conjugates 
Target cells / 
Indications / 
Functions. 
Advantages / features 
Efavirrenz Tuftsin-conjugated PPE 
dendrimers  
HIV Targeted delivery to macrophages 
Lamivudine Mannose-capped PPE 
dendrimers 
HIV  Increase the cellular uptake, 
reduced cytotoxicity. 
SiRAN Amino terminated 
carbosilane dendrimers 
Lymphocytes Reduced HIV infection, in-vitro 
Sulphated  
Oligosaccharides 
Polylysine dendrimers HIV Higher activity due to dendrimers 
product. 
Galatosaccharide 
Analogues 
Multivalent phosphorus 
containing catanionic 
dendrimers 
HIV-1 Higher stability and anti-viral 
property, lower toxicity. 
Doxorubicin 2,2bis(hydroxylmethyl) 
propanoic dendrimers  
Colon carcinoma cells 
of rat 
In vitro and in vivo, dendrimers 
product was ten times less toxic. 
SN38 G3.5 PAMAM dendrimers. Hepatic colorectal 
cancer cells  
Increase oral bioavailability and 
decrease gastrointestinal toxicity 
Boron EGF-carrying PAMAM 
dendrimers. 
Neuron capture 
technology 
Intratumoral injection or CED  
EGFR siRNA Dendriworms Knockdown EGFR 
expression  
IV or CED 
Plasmid pEGFP-N2 Angiopep-carrying 
PGEgylated PAMAM 
dendrimers G5.0 
Encode green 
fluorescence protein 
IV 
 
 
 
Drugs/therapeutics Target 
cells/Diseases 
Types of QDs Efficiency 
Saquinavir HIV-1 Carboxyl-terminated 
QDs 
High site-specificity andcross BBB 
Doxorubicin Ovarian cancer Mucin1-aptamer QD Targeting and controlled drug delivery to cancer 
cells.  
5-flurourasil Breast cancer ZnS QDs Enhance drug uptake 
Daunorubicin Leukaemia CdTe QDs Inhibit multidrug resistance. 
Daunorubicin Leukaemia CdS QDs High accumulation on target 
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LIPOSOMES:- 
Liposomes are lipid vesicular systems. These are composed 
of an aqueous core enclosed by natural or synthetic 
phospholipid bilayers.Theaqueous core used to encapsulate 
hydrophilic drugs, as well as and amphiphilic drugs can be 
solubilized within the phospholipid bilayers. Depending on 
the structure of the lipid bilayers liposomes can be classified 
as  
(a) Small unilamellar vesicles (SUV)  
(b) Large unilamellar vesicles and (LUV) 
 (c) multilamellar vesicles (MLVs).  
Liposomes were first introduced for drug delivery in 1965. 
[8] And in recent studies, these are the more  widely used 
Nano-pharmaceutical carriers. Liposomes are rapidly 
cleared from blood by phagocytic cells and they possess a 
low transport rate. But these disadvantages can be overcome 
by coating the surface with a biocompatible and inert 
polymer such as PEG or by incorporating targeting ligands. 
[9]Liposomal formulations are well used for delivering 
chemotherapeutic and anticancer agents. Successful delivery 
of Placitaxel can be done by conjugating liposome with poly 
(d, l-lactic acid) - polyethylene glycol [PLA-PEG] [52] 
 
Table6:-Drugs those delivered via Liposomes 
             Therapeutics Typeof liposome Indications 
Tppotecan+Vincristin PEG-Liposome Brain Cancer 
Lrinotecan+Cisplastin Mixture of two Liposome Small-Cell lung cancer 
siRNA+Doxorubicin PEG-Liposome MDR-Breastcancer 
Doxorubacin+verapamil Transferrin-(TF)Conjugated PEG-Liposome MDR-Leukemai 
Budesonide Small molucular Liposome Asthma 
Ketotifan Small molucular Liposome Asthma 
VEGF gene Gene liposome Pulmonary Hypertension 
Amiloride hydrochloride Small molucular Liposome Cystic Fibrosis 
Tobramycin Small molucular Liposome Pulmonary Infection 
Interlukin-2 Protein Liposome Lung Cancer 
Insulin Protein Liposome Diabetes 
               VEGF= Vascular endothelial growth factor 
Table 7:- opthalmic drugs those can be delivered via Liposome. 
        Drug   Types of liposome             Effects 
Diclofenac  Coated with low molucular weight chitosan High cornal permeation, better sustained release  
Ciprofloxacin Liposomal Hydrogel Fivefold higher transcorneal permeation 
Demeclocycline Not available Effect of drug lasts for longer peroid of time 
Plasmid DNA Cationic Liposome Increased transfection efficacy of pDNA 
 
 
POLYMERIC NANOPARTICLES:- 
Synthetic and semi synthetic polymers are a very potential media for Nano-technology based drug delivery.They have 
advantages like increased efficacy, lower toxicity, controlled release rates, sustained bioactivity, manufacturing reproducibility, 
higher stability, lesser administration frequency and capability of co delivering drugs resulting in synergistic effects.[10] Some 
polymers used for manufacturing nanoparticles are poly (lactic acid) [PLA], poly (lactic-co-glycolic acid) [PLGA], poly (ethylene 
glycol- co(lactic-glycolic acid)), poly (methyl) methacrylate, poly caprolactone) and poly (alkyl) cyanoacrylates. PNPs are 
produced by pairing with PEG to provide prolonged systemic circulation time. [11] 
Table 8:- Drugs those can be delivered via polymeric Nanoparticles 
Therapeutics Type of polymer / 
Fictionalization on  
  Indication /Activity          Effect 
Paclitaxel  Aptamer-PEG-PLGA Golimas Enhanced delivery 
Cisplatin Aptamer-PEG-PLGA Prostate cancer Higher efficiency 
Vincristine+Verapamil PLGA Hepatocellular carcinoma Reduced multidrug resistance 
Doxarubasin+Cyclosporine A PLGA Various cancers Synergistic effect 
Zidovudine Poly(isohexyl cyante) Targeting lymphoid tissue Drug level is four times higher 
Zidovudine Polyhexylcyanoacrylate Targeting lymphoid tissue Higher Zidovudine levels in the 
body 
Stavudine Polybeutilcyanoacrylate(PB
CA) 
HIV/AIDS 8-20 times higher permeation 
Lamivudine Methylmethacrylatesulfopr
opylmethacrylate 
HIV/AIDS 100% increased BBB 
permeation 
Nerve growth factor (NGF) Polysorbate 80 coated PBCA Parkinsonism Improved transport across the 
BBB 
Amphotericin B PLA-b-PEG Neurodegenerative diseases Improved transport across the 
BBB. 
PACA=polyalkylcyanoacrylate, PLGA= poly ((lactide-co-glycolide), PLA-b-PEG =Polysorbate 80 coated poly (lactic acid)-b-poly 
(ethylene glycol) 
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FDA APPROLVED, MARKETED 
NANOPHARMACEUTICALS:- 
There are a number of FDAapproved, marketed nanopharma
ceuticals [12] for the intravenous administration route (Tabl
e 2) as well as the nonintravenous route (Table 9 and Table 4
).However, numerous nanopharmaceuticals are still at the de
velopmentor clinical trial phase due to the extremely comple
x nature of human medicinal applications. This chapterwill di
scuss approved nanopharmaceuticals for nanomedicine deliv
ery (from a design and development perspective) by various 
administration routes including parenteral, oral, transdermal
 and pulmonary.  In this chapter, the following terms are use
d interchangeably:  nanodrugs, nanomedicines and nanophar
maceuticals.
 
 
Table 9:- select list of FDA-approved and marketed Nanopharmaceuticals products foe Intravenous (I.V) route of 
administration. 
Drug Nanotechnology Brand name Company Therapeutic Area 
Doxorubicin PEGlyated lipoomes Doxil 
Caelyx 
othroBiotech 
Scherimg-plough 
Metastatic ovarian cancer and 
AIDS related Kaposi`s sarcoma 
Doxorubicin Liposomes Myocet Zeneous pharma Metastatic cancer 
Paclitaxel Albumin-bound-
nanoparticals 
Abraxane Abraxis Bioscience  Various cancers 
Paclitaxel Polymeric micelles Genesol-PM Samyang Various cancers 
Amphotericin B Liposomes Ambisone NeXstsr 
pharmaceuticals  
Fungal infection 
Amphotericin B  Phospholipid complex Abelcet 
 
Enzon Invasive fungal infection 
Propofol Lipid emulsion Diprivan AstraZeneca Anesthesia 
Cytarabine Liposomes Depocyt Skyepharma  
Enzon 
Lymphomatous meningitis 
Daunorubicin 
Citrate 
Liposomes Daunoxome 
 
Gilead science  Advanced HIV related Kaposi`s 
sarcoma 
Adenosine 
deaminase 
PEGylation Adagen Enzon Enzyme replacement therapy in 
immunodeficiency diseases. 
Iron oxide Super paramagnetic iron 
oxide nanoparticals coated 
with carboxydextran  
Resovist 
 
Bayer-schering 
pharma AG 
Organ-specific MRI contrast 
agent  
Iron oxide Iron oxide nanoparticals Feridix I.V AMAG 
pharmaceuticals 
MRI constrast agent  
 
 
Table 10:- select list of FDA approved and marketed Nanopharmaceuticals products for oral and pulmonary route of 
administration 
Route Drug Nanotechnology Brand 
Name 
Company Therapeutic Area 
 
 
 
 
 
 
 
Oral 
Sirolimus Nanocrystal Rapamune Wyeth, Elan Transplants 
Fenofibrate Nanocrystal TriCor Abbott Primary  
Hypercholestremia 
Fenofibrate Nanocrystal Triglide Skyepharma Lipid Disorders 
Aprepitant Nanocrystal Emend Merck, Elan Nausea in Chemotherapy 
Megestrol Acetate Nanocrystal Megace ES Per pharma, Elan Antianorexic 
Morphine sulphate Nanocrystal Avinza King pharma, Elan Psycho-stimulant 
Dexmethylphenidate HCL Nanocrystal Folacin XR Novartis, Elan Attention deficit 
disorder 
Methylphenidate HCL Nanocrystal Ritalin LA Novartis, Elan Attention deficit 
disorder 
Tizanide HCL Nanocrystal Zanaflex 
Capsule 
Acorda Inc Muscle relaxant 
Cyclosporine A SMEDDS Neoral Novartis Transplant 
Saquinavir SMEDDS Forovase Roche Antiviral 
Ritonavir SMEDDS Norvir Abbott Laboratories Antiretroviral 
 
 
 
 
 
 
 
Pulmonary 
Artificial lung surfactant 
Replacement 
Synthetic 
recombinant 
polypeptide 
liposomal lung 
surfactant 
Surfaxin Drug Delivery Labs Respiratory distress 
syndrome 
Artificial lung surfactant 
Replacement 
Natural bovine 
lung extract 
Survanta Abbott Labs Respiratory distress 
syndrome 
Artificial lung surfactant Synthetic lung Exsurf GlaxoAbbottLabsSm Respiratory distress 
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Replacement surfactant 
(protein free) 
ithKline syndrome 
Artificial lung surfactant 
Replacement 
Natural porcine 
lung extract  
Curosurf Dey Respiratory distress 
syndrome 
Artificial lung surfactant 
Replacement 
Natural bovine 
lung extract 
Alveofact Boehringer  
Ingelheim 
Respiratory distress 
syndrome 
 
Table11:- select list of FDA approved and marketed nanopharmaceuticals products for subcutaneous, Intramuscular, 
Transdermal/Dermal, ophthalmic, Intravitral route of administration. 
Route Drug Nanotechnology Brand Name Company Therapeutic Area 
 
 
 
 
 
 
Subcutaneous 
 
Interferon alfa-
2a 
PEGylation Pegasys Nekter 
Hoffmann-
La 
Roche 
Hepatitis C infection 
hGH(Human 
Growth 
Hormones 
PEGylation Somavert Netker  
Pfizer 
Acromegaly 
Recombinant 
methionly 
human G-CSF 
PEGylation Neulasta Amgen Neutropenia  
Glatiramer 
acetate 
Copolymer of L-glutamic acid,  
L-analine, 
L-tyrosine,L-lycine                       
Copaxone Teva Multiple sclerosis 
Amphotericin B Lipid colloidal dispersion Amphotec Sequus Invasive 
aspergillosis 
Interferon alfa-
2b 
PEGylation PEGIntro Enzon  
Schering 
plough 
Hepatitis C infection 
Asparginase PEGylation Oncaspar Enzon Leukemia 
Intramuscular Hepatitis A 
vaccine 
IRIV(immunopotentiating 
reconstituted influenza 
virosome) 
Epaxel Berna 
Biotech 
Hepatitis A 
immunization 
Transdermal 
/Dermal 
 
Estradiol Micellar nanoparticals  Estrasorb BioSante Menopause 
Estradiol Estradialgel incorporating 
calciumphosphate nanoparticals  
Elestrin Novavax Menopause 
Lidocain Liposomes LMX-4 Ferndale 
Laboraterie
s 
Topical anesthenia 
Ophthalmic Cyclosporine A Lipid emulsion Restasis Allergan Dry eye 
Difluprednate Lipid emulsion Durezol Siron 
therapeutic
s 
Corticosteroid 
Intravitreal Anti-VEGF PEGylation Macugen OSI 
pharmaceut
icals 
Masculardegneratio
n 
 
APPROVED NANOPHARMACEUTICAL PRODUCTS: 
PARENTERAL DRUG DELIVERY:- 
The parenteral administration route can directly access syste
mic circulation with  a rapid  onset  of drug  action,  
achieving  an advanced  molecular  targeting  to  specific  
organs  and  tissue  sites [13]. However, there are certain 
classic disadvantages with this approach, namely, insufficient 
drug accumulation at  target  sites  while  large  amounts  are  
dissipated  and/or  undesirable  drug localization at normal 
tissue sites [14]. Given these drawbacks, there is extensive re
search ocussed on increasing efficiency and bioavailability of 
nanomedicine delivered parenterally. Cur-rent strategies 
under investigation include the following: 
 Creating a protective barrier around the nanomedicine
s:  This can be  accomplished  by  creating  satiric  
hindrance,  hydrodynamic  volume  effects  and/or  
charge  repulsions  around the nanomedicine. For 
example, polyethylene glycol (PEG)an  FDA‐approved  
polymeric excipient, provides both steric hindrance an
d hydrodynamic volume effects for the protection of na
nomedicines with an extended period of time resulting 
in enhanced circulation activity. 
 Stimuli‐triggered systems: Examples include ultrasonic,
 magnetic,electric and light from external‐regulated sti
muli as well as thermo‐sensitive, pH‐sensitive and enzy
me‐substrate reactions  
following as self‐regulated stimuli [15]. 
 For the parenteral drug delivery of nanomedicines, intr
avenous injection can be used for certain drugs having l
ong half‐lives.  Additionally, long‐acting parentral inject
ions are also administered through intramuscular and s
ubcutaneous routes [16]. 
APPROVED NANOPHARMACEUTICAL PRODUCTS: ORAL 
DRUG DELIVERY:- 
Oral delivery is the most common administration route.  This
 is mainly because of its high level of patient compliance due 
to its noninvasive nature, simplicity and convenience.  Nano
medicines based on oral drug delivery have been extensively 
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investigated and  have  resulted  various approved, marketed 
products. However, the oral delivery of liposome’s has been s
omewhat limited 
due totheir unpredictable absorption profiles and the rapid d
egradation of liposomes in the GI tract via interaction with bi
le salts [17, 18].    
Some advantages of polymer 
based nanomedicine include the following: 
 increasing bioavailability with enhanced water solubilit
y of hydrophobic 
drugs due to a large specific surface area; 
 ability to protect biologically unstable drugs from the h
ostile  environment of the gastrointestinal tract; 
 extending  drug  residence  time  through  strong  
mucoadhesive  properties; 
 controlled drug release; 
 facilitating  transport  of  the  drug  through  the  
epithelial  membrane via endocytosis; 
 bypassing or inhibiting efflux pumps such as 
glycoprotein;  and 
 Targeting specific carriers for receptor 
mediated transport. 
APPROVED NANOPHARMACEUTICAL PRODUCTS: 
PULMONARY DRUG DELIVERY:- 
The lung is an attractive target for drug delivery because it of
fers a noninvasive means to provide not only local lung effect
s but also possible high systemic bioavailability, avoidance of
 first‐pass metabolism, faster onset of therapeutic action, and
 the availability of a large surface area [19, 20].  Nanomedicin
es for pulmonary drug delivery have many advantages,such a
s the ability to: 
 achieve a relatively uniform drug distribution; 
 enhance the solubility of the drug beyond its own aque
ous solubility; 
 achieve a sustained‐release effect of the inhaled nondru
g; 
 deliver macromolecules; 
 reduced toxic side effects; 
 improve patient compliance; and 
 Increase drug internalization by cells. 
APPLICATIONS OF NANOBIOTECHNOLOGY IN 
MEDICAL AND CLINICAL FIELDS 
a) Diagnostic applications 
Current diagnostic methods for most of diseases.Depend on 
the manifestation of visible symptoms before medical 
professionals can recognize that the patient suffers from a 
specific illness. But by the time those symptoms have 
appeared, treatment may have a decreased chance of being 
effective. Therefore the earlier a disease can be detected, the 
better the chance for a cure is. Optimally, diseases should be 
diagnosed and cured before symptoms even manifest 
themselves. Nucleic acid diagnostics  will play a crucial role 
in that process, as they allow the detection of pathogens and 
diseases/diseased cells at such an early symptomless stage 
of disease progression that effective treatment is more 
feasible. Current technology, such as- polymerase chain 
reaction (PCR) leads toward such tests and devices, but 
nanotechnology is expanding the options currently available, 
which will result in greater sensitivity as well as far better 
efficiency and economy. 
1. Detection:- 
Many currently used/conventional clinical tests reveal the 
presence of a molecule or a disease causing organism by 
detecting the binding of a specific antibody to the disease-
related target. Traditionally, such tests are performed by 
conjugating the antibodies with inorganic/organic dyes and 
visualizing the signals within the samples through 
fluorescence microscopy or electronic microscopy. However, 
dyes often limit the specificity and practicality of the 
detection methods. Nanobiotechnology offers a\ solution by 
using semiconductor nanocrystals (also referred to as 
"quantum dots"). These minuscule probes can withstand 
significantly more cycles of excitations and light emissions 
than typical organic molecules, which more readily 
decompose [21]. 
2. Individual target probes 
Despite the advantages of magnetic detections, optical and 
colorimetric detections will continue to be chosen by the 
medical community. Nanospheres(Northbrook, Illinois) is 
one of the companies that developed techniques that 
allow/allowing doctors to optically detect the genetic 
compositions of biological specimens. Nano gold particles 
studded with short segments of DNA form the basis of the 
easy-to-read test for the presence of any given genetic 
sequence. If the sequence of interest in the samples, it binds 
to complementary DNA tentacles on multiple Nanospheres 
and forms a dense web of visible\ gold balls. This technology 
allows/facilitates the detection of pathogenic organisms and 
has shown promising results in the detection of anthrax, 
giving much higher sensitivity than tests that are currently 
being used [22]. 
3. Protein chips 
Proteins play the central role in establishing the biological 
phenotype of organisms in healthy and diseased states and 
are more indicative of functionality. Hence, proteomics is 
important in disease diagnostics and pharmaceutics, where 
drugs can be developed to alter signaling pathways. Protein 
chips can be treated with chemical groups, or small modular 
protein components, that can specifically bind to proteins 
containing a certain structural or biochemical motif [23]. 
Two companies currently operating in this application space 
are Agilent, Inc. and Nan oink, Inc. Agilent uses a non-contact 
ink-jet technology to produce microarrays by printing oligos 
and whole cDNAs onto glass slides at the Nanoscale. Nan 
oink uses dip-pen nanolithography (DPN) technology to 
assemble structure on a Nanoscale of measurement. 
4. Sparse cell detection 
Sparse cells are both rare and physiologically distinct from 
their surrounding cells in normal physiological conditions 
(e.g. cancer cells, lymphocytes, fetal cells and HIV-infected 
Tcells). They are significant in the detection and diagnosis of 
various genetic defects. However, it is a challenge to identify 
and subsequently isolate these sparse cells. 
Nanobiotechnology presents new opportunities for 
advancement in this area. Scientists developed nanosystems 
capable of effectively sorting sparse cells from blood and 
other tissues. This technology takes advantage of/exploits 
the unique properties of sparse cells manifested in 
differences in deformation, surface charges and affinity for 
specific receptors and/or ligands. For example, by inserting 
electrodes into microchannels, cells can be precisely sorted 
based on surface charge. They can also be sorted by using 
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biocompatible surfaces with precise nonporous. The nano-
biotechnology center at Cornell University (NBTC) is 
currently using these technologies to develop powerful 
diagnostic tools for the isolation and diagnosis of various 
diseases [24]. 
5. Nanotechnology as a tool in imaging 
Intracellular imaging can be made possible through labelling 
of target molecules with quantum dots (QDs) or synthetic 
chomophores, such as fluorescent proteins that will facilitate 
direct investigation of intracellular signaling complex by 
optical techniques, i. e. confocal Fluorescence microscopy or 
correlation imaging [25] 
(b)Therapeutic applications: 
Nanotechnology can provide new formulations of drugs with 
less side effects and routes for Drug delivery. 
1. Drug Delivery: 
Nanoparticles as therapeutics can be delivered to targeted 
sites, including locations that cannot be easily reached by 
standard drugs. For instance, if a therapeutic can be 
chemically attached to a nanoparticle, it can then be guided 
to the site of the disease or infection by radio or magnetic 
signals. These nanodrugs can also be designed to "release" 
only at times when specific molecules are present or when 
external triggers (such as infrared heat) are provided. At the 
same time, harmful side effects from potent medications can 
be avoided by reducing the effective dosage needed to treat 
the patient. By encapsulating drugs in nanosized materials 
(such as organic dendrimers, hollow polymer capsules, and 
nanoshells), release can be controlled much more precisely 
than ever before. Drugs are designed to carry a therapeutic 
payload (radiation, chemotherapy or gene therapy) as well 
as for imaging applications [26].  
2. Gene delivery 
Current gene therapy systems suffer from the inherent 
difficulties of effective pharmaceutical processing and 
development, and the chance of reversion of an engineered 
mutant to the wild type. Potential immunogenicity of viral 
vectors involved in gene delivery is also problematic [2and 
nanoparticle-based nonviral vectors (usully50-500 nm in 
size) in transportation of plasmid DNA described. Therefore, 
successful introduction of less immunogenic nanosize gene 
carriers as a substitution of the disputed viral vectors seems 
beneficial in repairing or replacing impaired genes in human 
[27]. 
3. Liposomes 
A liposome being composed of a lipid bilayer can be used in 
gene therapy due to its ability to pass through lipid bilayers 
and cell membranes of the target. Recent use of several 
groups of liposomes in a local delivery has been found to be 
convincingly effective [28, 29]. Liposomes can also help 
achieve targeted therapy. Zhang et al demonstrated 
widespread reporter expression in the brains of rhesus 
monkeys by linkingnanoparticle (such as polyethylene 
glycol) treated liposomes to a monoclonal antibody for 
human insulin reporter. These successful trials reflect the 
future of targeted therapy and the importance of nanometer-
sized constructs for the advancement of molecular medicine. 
4. Surfaces 
In nature, there are a multitude of examples of the 
complicated interactions between molecules and surfaces. 
For example, the interactions between blood cells and the 
brain or between fungal pathogens and infection sites rely on 
complex interplays between cells and surface characteristics. 
Nanofabrication unravels the complexity of these 
interactions by modifying surface characteristics with 
nanoscale resolutions, which can lead to hybrid biological 
systems. This hybrid material can be used to screen drugs, as 
sensors, or as medical devices and implants. Nanosystems, 
owned by the Irish drug company Elan, developed a polymer 
coating capable of changing the surface of drugs that have 
poor water solubility [30]. 
5. Bimolecular Engineering 
The expense and time involved in traditional biomolecule 
designing limit the availability of bioactive molecules. 
Nanoscale assembly and synthesis techniques provide an 
alternative to traditional methods. Improvements can b 
achieved due to the ability to carry out chemical and 
biological reactions on solid substrates, rather than through 
the traditional solution based processes. The use of solid 
substrate usually means less waste and the ability 
tomanipulate the biomolecule far more precisely. EngeneOS 
(Waltham, Massachusetts) pioneered the field of 
biomolecular engineering. To address this issue, 
nanotechnological tools in human gene therapy have been 
tested company developed the engineered genomic 
operating systems that create programmable biomolecular 
machines employing natural and artificial building blocks. 
These biomolecules machines have broad range of 
commercial applications-as biosensors, in chemical synthesis 
and processing, as bioelectronic devices and materials, in 
nanotechnology, in functional genomics and in drug 
discovery. 
6. Biopharmaceuticals 
Nanobiotechnology can develop drugs for diseases that 
conventional pharmaceuticals cannot target. The 
pharmaceutical industry traditionally focuses on developing 
drugs to treat a defined universe of about five hundred 
confirmed disease targets. But approximately 70 to 80 
percent of the new candidates for drug development fail, and 
these failures are often discovered late in the development 
process, with the loss of millions of dollars in R&D 
investments. Nanoscale techniques for drug development 
will be a boon to small companies, which cannot employ 
hundreds of organic chemists to synthesize and test 
thousands of compounds. Nanobiotechnology brings the 
ability to physically manipulate targets, molecules and atoms 
on solid substrates by tethering them to biomembranes and 
controlling where and when chemical reactions take place, in 
a fast process that requires few materials (reagents and 
solutions). This advance will reduce drug discovery costs, 
will provide a large diversity of compounds, and will 
facilitate the development of highly specific drugs. Potential 
Pharmaceuticals (Louisville, Kentucky) is an early-stage 
company that is attempting to streamline the drug 
development process with the use of nanotechnologies 
(Harvard Business School 2001). 
7. Nanotechnology in cardiac therapy 
Nanotechnology is currently offering promising tools for 
applications in modern cardiovascular science to explore 
existing frontiers at the cellular level and treat challenging 
cardiovascular diseases more effectively. These tools can be 
applied in diagnosis, imaging and tissue engineering [31]. 
Miniaturized Nanoscale sensors like quantum dots (QDs), 
nanocrystals, and nanobarcodes are capable of sensing and 
monitoring complex immune signals in response to cardiac 
or inflammatory events [32]. Nanotechnology can also help 
detect and describe clinically-significant specific mechanisms 
implicated in cardiac disorders. In addition, it is useful in 
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designing atomic-scale machines that can be incorporated 
into biological systems at the molecular level. 
8. Nanotechnology in dental care 
Nanotechnology will have future medical applications in the 
field of dentistry. The role of nanodentistry by means of the 
use of nanomaterials, biotechnology, and nanorobotics will 
ensure better oral health .Millions of people currently 
receiving poor dental care will benefit from such remarkable 
breakthrough in the science of dental health [33,34]. 
Moreover, nanodental techniques in major tooth repair may 
also evolve. Reconstructive dental nanorobots could be used 
in selective and precise occlusion of specific tubules within 
minutes, and this will facilitate quick and permanent 
recovery.  
9. Nanotechnology in orthopedic applications 
Nanomaterials sized between 1 and 100 nm have role to play 
as new and functional constituents of bones being also made 
up of nanosized organic and mineral phases [35,36]. 
Nanomaterials, nanopolymers, carbon nanofibers, 
nanotubes, and ceramic nanocomposites may help with more 
efficient deposition of calcium-containing minerals on 
implants. Based on these evidences and observations, 
nanostructure materials represent a unique realm of 
research and development that may improve the attachment 
of an implant to the surrounding bone matters by enhancing 
bone cell interactions, and this will indeed aid in improving 
orthopedic implant efficacy while drastically minimizing 
patient compliance problems. 
OPPORTUNITIES AND CHALLENGES OF 
NANOTECHNOLOGY IN THE GREEN ECONOMY 
The potential nanotechnology impact on green 
innovations:- 
Green nanotechnology is expected to play a fundamental role 
in bringing a key functionality across the whole value chain 
of a product, both through the beneficial properties of NMs 
included as a small percentage in a final device, as well as 
through nano-enabled processes and applications without 
final products containing any NMs [36,37]. However, most of 
the potential green nano-solutions are still in the lab/start-
up phase and very few products have reached the market to 
date. Further studies are necessary to assess the 
applicability, efficiency and sustainability of 
nanotechnologies under more realistic conditions, as well as 
to validate NM enabled systems in comparison to existing 
technologies. The following paragraphs will describe the 
potential fields of application for green nanotechnology 
innovations. 
1. Nanomaterials for energy conversion 
One of the most interesting and most flexible renewable 
energy technologies is the direct conversion of sunlight into 
electric power: the photovoltaic effect. Carbon NMs, 
including C60 fullerenes, carbon nanotubes (CNTs) and 
graphene have been studied as extremely efficient electron 
acceptors in polymer and quantum dot solar cells. Relatively 
new, dye sensitized solar cells are of great promise. In these 
devices, a nanocrystalline mesoporous titanium dioxide 
(TiO2) film, with a monolayer of the charge transfer dye 
attached to its surface, is pasted on a transparent conductive 
substrate [38,39].  
Another important future energy option is the hydrogen gas 
as an endless source of clean fuel for many applications [40]. 
Semiconductor NMs, e.g. TiO2 and cadmium sulfide 
nanostructures, have been studied as efficient catalysts for 
water conversion into oxygen and hydrogen [40–43]. 
Moreover, nano-structured carbons, metal-organic 
frameworks and polymers as well as metal hydrides and 
related complex hydrides are examples of investigated NMs 
for hydrogen storage and transportation for high hydrogen 
capacity and minimal deterioration during hydrogenation. 
2. Nanomaterials for energy storage 
Nanotechnology may have a profound influence on electrical 
storage technologies, i.e. batteries and electrochemical super 
capacitors [44]. Redox-based supercapacitors with nano-
structured electrode materials have shown the potential to 
combine the high energy density of conventional batteries 
with the high power capabilities of electrostatic capacitors at 
the lab scale. Mixed metal oxides, e.g. ruthenium oxide 
(RuO2), manganese oxide (MnO2), magnetite (Fe3O4, CNTs 
[48], grapheme and carbon-metal oxide composites have 
been investigated as electrode NMs aimed at a high specific 
capacity and rate capability Concerning rechargeable lithium 
batteries, the energy densities and the performances of these 
devices largely depend on the physical and chemical 
properties of the electrode material [45].  
3. Nanomaterials for water clean-up technologies 
Nanotechnology-enabled water and wastewater treatment 
promises not only to overcome major challenges faced by 
existing treatment technologies, but also to provide new 
treatment capabilities that could allow economic utilization 
of unconventional water sources to expand the water supply 
[46]. Interesting applications may include the incorporation 
of functional NMs, such as metal-oxide NPs (aluminum oxide, 
TiO2 and zeolite), anti-microbial NMs (silver-NPs (Ag-NPs) 
and CNTs) and photo catalytic NMs (bimetallic-NPs, TiO2) 
into membranes in order to improve their permeability, 
fouling resistance, biofilm control, mechanical and thermal 
stability, as well as to provide pollutant degradation and self-
cleaning ability [47] 
4. Nanomaterials for construction industry 
Manufactured NMs and nanocomposites offer great 
opportunities in the construction and related infrastructure 
industries. Strength, durability, and lightness of various 
materials [48, 49], as well as heat-insulating, self-cleaning, 
fire-retardant, anti-fogging and sensing structural health 
properties may be improved or provided de novo by NMs.
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Table 12:-Example relationships among guiding principles for a green economy and the opportunities and challenges 
for nano-applications 
                                 Guiding principles for a green economy 
    P1 Is a means for achieving sustainable development. 
    P2 Creates decent work and green jobs 
    P3 Improves governance and the rule of law-by being inclusive, democratic, participatory, accountable, 
transparent and stable. 
    P4 Is equitable, fair and just between and within countries and between generations. 
    P5 Reduce poverty and increases well-being livelihoods, social protection and access to essential 
services. 
    P6 Protects biodiversity and ecosystem 
    P7 Is resource and energy efficient 
    P8 Respects planetary boundaries or ecological limits or scarcity. 
    P9 Uses integrated decision making 
    P10 Internalizes externalizes 
    P11 Measure beyond gross domestics product indicators and metrics. 
 
Example opportunities for nano-applications in a green economy (and related principles) 
Energy conversion 
and storage 
-Small energy nanotechnology can improve power delivery systems to be more efficient, reliable 
and safe (P1, P2, P5) 
-Nano-devices may trade on renewable energy produced through naturally replenished 
resources, i.e. sunlight and wind. this may reduce fossils as energy resources and the impact for 
the greenhouse gas emissions balance (P3 ,P4, P5,P6 ,P7 ,P9) 
-Energy different nanotechnology requires less energy to perform the same function. Created 
energy (P7, P8 ,P10) 
Water cleanup 
technologies 
-Design  nano-enabled  infrastructure necessary to manage water and keep  it clean is linked to 
prospects for economic development and livelihood conditions (P1,P2) 
-Access to clean water and adequate sanitation is a basic human right and is critical to the 
alleviation of poverty (P3,P4,P5) 
Construction 
industry  
-nanotechnologyaims to increase the efficiency buildings use resources-energy, water, materials. 
-while reducing building impacts on environment and human health through better siting, 
construction, and removal (P1,P2,P6,P7,P8,P10) 
other applications -Nano-enabled applications may provide slow release and dosage of fertilizers and an efficient 
water resources for plants. This may contribute to a great agriculture productivity, especially in a 
countries with prolonged dry spells(P1, P2, P4, P5) 
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